Literature DB >> 31302632

Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE.

Ezgi Ilan1, Irina Velikyan1, Mattias Sandström1, Anders Sundin1, Mark Lubberink1.   

Abstract

PET/CT with 68Ga-DOTA-somatostatin analogs has been tested for therapy monitoring in patients with neuroendocrine tumors (NETs). However, standardized uptake values (SUV) in tumors do not correlate with the net influx rate (Ki), as a representation of the somatostatin receptor (SSTR) expression. In this study, tumor-to-blood-ratio (TBR) was evaluated as an alternative tool for semi-quantitative assessment of 68Ga-DOTATOC and 68Ga-DOTATATE tumor uptake and as a therapy monitoring tool for patients with NETs.
Methods: Twenty-two NET patients underwent a 45-min dynamic PET/CT scan after injection of 68Ga-DOTATOC and/or 68Ga-DOTATATE. Ki was determined using the Patlak method and TBR was calculated for the 40-45 min time interval.
Results: A linear relation was found between Ki and TBR, with a square of Pearson correlation (R2) of 0.98 and 0.93 for 68Ga-DOTATOC and 68Ga-DOTATATE, respectively.
Conclusion: High correlation was found between Ki and TBR. Hence, TBR reflects SSTR density more accurately than SUV and is suggested as the preferred metrics for semi-quantitative assessment of 68Ga-DOTATOC and 68Ga-DOTATATE tumor uptake.
Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  68Ga-DOTATOC/68Ga-DOTATATE; Molecular Imaging; Net influx rate; Neuroendocrine; Neuroendocrine tumors; PET/CT; SUV; Tumor-to-blood ratio

Year:  2019        PMID: 31302632     DOI: 10.2967/jnumed.119.228072

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake".

Authors:  Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe; Martin A Lodge; Ralph A Bundschuh
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody.

Authors:  Yan Wang; Donghui Pan; Chenrong Huang; Bingliang Chen; Mingzhu Li; Shuaixiang Zhou; Lizhen Wang; Min Wu; Xinyu Wang; Yicong Bian; Junjie Yan; Junjian Liu; Min Yang; Liyan Miao
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

3.  Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

Authors:  M C F Cysouw; B H E Jansen; M Yaqub; J Voortman; A N Vis; R J A van Moorselaar; O S Hoekstra; R Boellaard; D E Oprea-Lager
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

4.  Dynamic 68Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas.

Authors:  Jana Ivanidze; Michelle Roytman; Myrto Skafida; Sean Kim; Shannon Glynn; Joseph R Osborne; Susan C Pannullo; Sadek Nehmeh; Rohan Ramakrishna; Theodore H Schwartz; Jonathan P S Knisely; Eaton Lin; Nicolas A Karakatsanis
Journal:  Radiol Imaging Cancer       Date:  2022-03

5.  Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.

Authors:  Philippe Thuillier; David Bourhis; Jean Philippe Metges; Romain Le Pennec; Karim Amrane; Ulrike Schick; Frédérique Blanc-Beguin; Simon Hennebicq; Pierre-Yves Salaun; Véronique Kerlan; Nicolas Karakatsanis; Ronan Abgral
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

6.  Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.

Authors:  Marta Opalińska; Karolina Morawiec-Sławek; Adrian Kania-Kuc; Ibraheem Al Maraih; Anna Sowa-Staszczak; Alicja Hubalewska-Dydejczyk
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-15       Impact factor: 6.055

Review 7.  18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Authors:  Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.